Abpro And Its Co-development Partner Celltrion Submitted An Investigational New Drug Application To FDA For ABP-102/CT-P72 HER2-Positive Cancers

Benzinga · 3d ago

Abpro Holdings and CELLTRION, INC. recently presented compelling preclinical results for ABP-102/CT-P72 at the American Association for Cancer Research (AACR) 2025 Annual Meeting and at the Society for Immunotherapy of Cancer (SITC) 40th Anniversary Annual Meeting, highlighting selective activity in HER2-high tumor models and lower activity on cells with normal-tissue–level HER2 expression in preclinical studies. In non-human primates, ABP-102/CT-P72 was well tolerated. Together, these findings support the potential for a favorable therapeutic index in clinical studies.

Upon FDA authorization to proceed, the planned phase 1 study will evaluate the safety, pharmacokinetics, and preliminary efficacy of ABP-102/CT-P72 in a dose-escalation and dose-expansion format. Data generated from the trial will inform dose selection and guide subsequent clinical development.